Spatial Repellents for the Prevention of Malaria in Kenya
Launched by UNIVERSITY OF NOTRE DAME · Feb 19, 2021
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
Spatial repellents (SRs) have been widely used for the prevention of mosquito bites but their protective efficacy (PE) in reducing mosquito-borne diseases has never been evaluated in Africa. To address this knowledge gap, western Kenya was selected as a site to estimate the impact of a transfluthrin-based spatial repellent on malaria-related outcomes in Busia County, where baseline malaria transmission ranges from 2.5 to 4.1 new infections per person per year.
A total of 5,984 children between 6 months and \<10 years of age will be enrolled in three separate cohorts (baseline, cohort 1 and...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged 6 months to \<10 years
- • Hb \> 5mg/dl
- • Sleeps in cluster \>90% of nights during any given month
- • No plans for extended travel (\>1month) outside of home during study
- • Not participating in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the Trial
- • Provision of informed consent form signed by the parent(s) or guardian
- • Children not on regular malaria prophylaxis° such as Proguanil
- • Willingness to take AL and no history of hypersensitivity to AL
- Exclusion Criteria:
- • Children \< 6 months or ≥ 10 years
- • Hb ≤ 5 mg/dL, or Hb \< 6mg/dL with signs of clinical decompensation
- • Sleeps in cluster \<90% of nights during any given month
- • Plans for extended travel (\>1month) outside of home during study
- • Participating or planned participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial
- • No provision of informed consent form signed by the parent(s) or guardian
- • Children on regular malaria prophylaxis° such as Proguanil
- • Unwillingness or refusal to take AL and history of AL hypersensitivity
- • Other malaria prophylaxis medicines: Mefloquine, Atavaquone/Proguanil (Malarone), Doxycycline, Tafenoquine, Sulfadoxine-Pyrimethamine (Fansidar), Amodiaquine and Co-trimoxazole (Septrin)
About University Of Notre Dame
The University of Notre Dame is a prestigious research institution dedicated to advancing knowledge and improving health outcomes through innovative clinical trials. Committed to excellence in research and education, the university leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies that address pressing medical challenges. With a focus on ethical practices and participant safety, the University of Notre Dame collaborates with healthcare professionals and community partners to translate scientific discoveries into effective therapies, ultimately enhancing patient care and contributing to the broader field of medical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Busia, Busia County, Kenya
Busia, Busia County, Kenya
Patients applied
Trial Officials
John P Grieco, Ph.D.
Study Director
University of Notre Dame
Eric Ochomo, Ph.D.
Principal Investigator
Kenya Medical Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials